Invitation to Roche’s Virtual Neurology/ACTRIMS Investor Event
2026-01-13
 We are pleased to invite investors and analysts to participate in our virtual event on Monday, 9 February 2026, to highlight Roche’s neurology pipeline and new data from the Phase III FENtrepid study evaluating fenebrutinib vs. Ocrevus (ocrelizumab) in PPMS, which will be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum from 5-7 February 2026. 16:30 - 17:30 CET / 15:30 - 16:30 GMT 10:30 - 11:30 am EST / 07:30 - 08:30 am PST Agenda Introduction Bruno Eschli, Head of Investor Relations Neurology pipeline update Hideki Garren, SVP, Global Head of Product Development Neurology Ph III (FENtrepid) fenebrutinib vs. Ocrevus in PPMS Amit Bar-Or, MD, FRCPC, Director, Center for Neuroinflammation and Experimental Therapeutics and Chief, Multiple Sclerosis Division, Department of Neurology Perelman Center for Advanced Medicine (PCAM), University of Pennsylvania Q&A The slides will be available for download at 15:30 CET on the day of the event. > click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice Best regards, | |
| Bruno Eschli Head of Investor Relations | Loren Kalm Head of Investor Relations, North America |
| Roche Investor Relations | |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com | |
Investors
Investor updates
stay updated
get the latest news and updates to your inbox.